Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer

Luca Gianni(Fondazione Michelangelo), Giuseppe Viale(University of Milan), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), I. Maffeis(Fondazione Michelangelo), Giancarlo Bisagni, Giampaolo Bianchini(Vita-Salute San Raffaele University), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Pinuccia Valagussa(Fondazione Michelangelo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Marco Colleoni(European Institute of Oncology), Stefania Zambelli(San Raffaele University of Rome)
npj Breast Cancer
January 10, 2022
10.1038/s41523-021-00377-8
Cited by 29

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k